These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 19432112)
1. [Prediction of vertebral strength using a CT based finite element method--clinical application in evaluation of the efficacy of alendronate]. Ohnishi I Nihon Rinsho; 2009 May; 67(5):932-7. PubMed ID: 19432112 [TBL] [Abstract][Full Text] [Related]
2. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Imai K; Ohnishi I; Matsumoto T; Yamamoto S; Nakamura K Osteoporos Int; 2009 May; 20(5):801-10. PubMed ID: 18800178 [TBL] [Abstract][Full Text] [Related]
3. Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method. Imai K J Bone Miner Metab; 2011 Nov; 29(6):645-51. PubMed ID: 21667358 [TBL] [Abstract][Full Text] [Related]
4. Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Mawatari T; Miura H; Hamai S; Shuto T; Nakashima Y; Okazaki K; Kinukawa N; Sakai S; Hoffmann PF; Iwamoto Y; Keaveny TM Arthritis Rheum; 2008 Nov; 58(11):3340-9. PubMed ID: 18975334 [TBL] [Abstract][Full Text] [Related]
5. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738 [TBL] [Abstract][Full Text] [Related]
6. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436 [TBL] [Abstract][Full Text] [Related]
7. [Assessment of bone quality. Effects of osteoporosis medications on structural and mechanical integrity of bone]. Mawatari T; Miura H; Iwamoto Y; Higaki H Clin Calcium; 2008 Mar; 18(3):354-63. PubMed ID: 18310824 [TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of lumbar vertebral strength in elderly women using computed tomography-based nonlinear finite element model. Imai K; Ohnishi I; Yamamoto S; Nakamura K Spine (Phila Pa 1976); 2008 Jan; 33(1):27-32. PubMed ID: 18165745 [TBL] [Abstract][Full Text] [Related]
9. Prediction of the vertebral strength using a finite element model derived from low-dose biplanar imaging: benefits of subject-specific material properties. Sapin-de Brosses E; Jolivet E; Travert C; Mitton D; Skalli W Spine (Phila Pa 1976); 2012 Feb; 37(3):E156-62. PubMed ID: 22290213 [TBL] [Abstract][Full Text] [Related]
10. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630 [TBL] [Abstract][Full Text] [Related]
11. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818 [TBL] [Abstract][Full Text] [Related]
12. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143 [TBL] [Abstract][Full Text] [Related]
13. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867 [TBL] [Abstract][Full Text] [Related]
14. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study. Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071 [TBL] [Abstract][Full Text] [Related]
16. [Drug therapy for prevention of falls and fractures]. Ringe JD Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362 [TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063 [TBL] [Abstract][Full Text] [Related]
18. Prediction of vertebral strength under loading conditions occurring in activities of daily living using a computed tomography-based nonlinear finite element method. Matsumoto T; Ohnishi I; Bessho M; Imai K; Ohashi S; Nakamura K Spine (Phila Pa 1976); 2009 Jun; 34(14):1464-9. PubMed ID: 19525837 [TBL] [Abstract][Full Text] [Related]
19. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571 [TBL] [Abstract][Full Text] [Related]
20. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR; JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]